Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
复制标题
DOI：
10.1016/s1470-2045(15)70122-1
复制
发表时间：
2015-05-01
期刊：
影响因子：
51.1
通讯作者：
Testori, Alessandro
中科院分区：
文献类型：
--
作者：
Eggermont, Alexander M. M.;Chiarion-Sileni, Vanna;Testori, Alessandro
背景Ipilimumab是一种被批准用于晚期黑色素瘤患者的治疗方法。我们的目的是评估ipilimumab作为辅助治疗完全切除的III期黑色素瘤患者复发的高风险。方法我们在III期皮肤黑色素瘤患者（排除淋巴结转移）中进行了一项双盲、3期试验
Background Ipilimumab is an approved treatment for patients with advanced melanoma. We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.Methods We did a double-blind, phase 3 trial in patients with stage III cutaneous melanoma (excluding lymph node metastasis